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Abstract 
 
 
Genetic screening for Down syndrome, and other genetic anomalies has developed in the 
last 50 years and in modern society, prenatal screening techniques is routinely and 
successfully used to detect Down syndrome. In this project our aim was to analyze some 
of the different techniques used in detecting these chromosomal disorders, specifically 
Down syndrome. The techniques have been analyzed, focusing on the ones that have the 
lowest risk to the unborn child and the mother, but at the same time having high detection 
efficiency. 
  
In order to achieve this goal, we primarily used scientific journals combined with 
statistical data and figures. Both non-invasive and invasive techniques were researched, 
and a conclusion was based on these results.  
 
In conclusion, a combination of Nuchal Translucency and Triple test will provide high 
detection efficiency of Trisomy 21. In a case of a positive result, the invasive technique 
QF-PCR will give the parents the most accurate results they need, in order to make a 
decision regarding their unborn child.  
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Introduction 
 
There is a lot of focus on genetic screening in the modern society. We consider this to be 
a societal and scientific problem due to the socioeconomic and moral dilemmas genetic 
screening causes.  
Prenatal screening can be an effective tool in detecting the probability of an unborn child 
being diagnosed with a genetic aberration which may result in physical malformations 
and/or psychological disorders. They can provide information about genetic defects of the 
fetus. The results of the techniques can give parents the necessary information which will 
help in their decision to terminate the pregnancy or not. Another advantage of using these 
technologies is that parents and specialists have a larger time frame to prepare for the 
special medical needs of the newborn.  
 
 
Down syndrome 
 
Trisomy 21, also known as Down syndrome, was described for the first time by the 
British physician John Down in 1866. Earlier on, before this first description of its 
characteristics, the syndrome was identified by the name “Mongolism”. It was only later 
that the actual cause was determined genetically. By that time researchers were urged to 
stop using this misleading name and use names like “Down’s syndrome/ anomaly” and 
“Trisomy 21 anomaly”(Girirajan 2009). 
 
 
Prevalence 
 
Down syndrome is so far the most common chromosomal disorder, and also the best 
studied and known (Chen 2006). It is the most common genetic cause of mental 
retardation in humans (Ghosh et. al. 2009). In general the syndrome is approximated to 
affect 1 in 800 live births, and in the United States the children born with Down 
syndrome are more than 5000 a year (Allen et. al. 2009). However, these figures can vary 
because of the most important factor- maternal age. A mother over the age of 35 has a 
higher risk of conceiving a child with Down syndrome. Some research suggests that this 
approximation can also vary depending on other factors like ethnic groups, environmental 
and genetic variations, and of course genetic predisposition to the anomaly (Girirajan 
2009).  
 
 
Down syndrome phenotype 
 
Individuals with trisomy 21 manifest typical and well studied physical characteristics 
(phenotypes). The features of Down syndrome include severe dementia (also known as 
cognitive impairment), typical facial and body anomalies, developmental delay, short 
torso and undeveloped muscle tone (also known as hypotonia), and defects on different 
organ systems (Girirajan 2009). Some of the most common facial and body features of an 
individual with Down syndrome are presented in Table 1 (Chen 2006). 
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Table 1 - Common phenotype of Down syndrome 
Characteristic Explanation 
Epicanthic folds “mongoloid eyes” 
Flat nasal bridge - 
Tongue protrusion - 
Brushfield spots Spots in the iris 
Large fontanels Large back head 
Small ears 66-89 % infants have hearing loss 
due to the undeveloped ears 
Sloping forehead - 
Short torso - 
Hypotonia Low muscle tone 
Laxity of the neck Looseness of the neck 
Narrow chest - 
Atlantoaxial instability Skeletal instability 
Hyper extensible finger 
joints 
Short and broad hands with elastic 
joints 
Increased space between 
big and 2nd toe 
- 
 
Along with the genetically inherited anomalies, patients with Down syndrome can 
develop numerous defects on the different systems in the body, especially heart defects 
(Girirajan 2009). Because of the extra genetic material of the 21st chromosome, patients 
with the condition are predisposed to leukemia, Alzheimer’s disease, testicular cancer and 
germ cell tumors (Patja et.al. 2006). The risk of a person with Down syndrome to develop 
other types of cancer is almost the same as for the general population however. (Patja et. 
al. 2006). 
 
 
Meiosis and Mitosis 
 
Human cell division is a very long and complicated process. The most important 
processes begin in the first and longest stage of the cell’s life, called Interphase. During 
this stage a cell starts preparing for Mitosis and Meiosis. In Fig. 1 we can see a schema of 
Iterphase stage.  
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Figure 1 Cellular cycle (Campbell et al 2008) 
 
G1 - Growth – In that phase the cell starts growing. There is a synthesis of structural and 
enzymatic protein.  
 
S – Synthesis – In this stage DNA duplication takes place.  
 
G2 - Protein synthesis – In this stage the cell prepares for Mitosis.  
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Mitosis begins after stage G2 and occurs in five steps, presented in detail in Fig. 2. 
 
 
Figure 2 Mitosis (Campbell et al 2008) 
 
On Fig. 3 we can see the differences between Mitosis and Meiosis.  
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Figure 3 - Mitosis and Meiosis overview (Campbell et al 2008) 
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Fig. 4 shows both processes of Meiosis – Meiosis I and II. These two processes are very 
important in the cell’s life, because if a nondisjunction happens it can lead to a 
chromosomal anomaly, for example Down’s Syndrome. 
 
 
 
Figure 4 - Meiosis II  (Campbell et al 2008) 
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Down syndrome karyotypes 
 
A human karyotype is the full set of chromosomes in a human cell and the normal 
karyotype consists of 46 chromosomes. According to their prevalence there are three 
basic types of Down syndrome, caused by a genetic nondijunction during meiosis or 
mitosis (Dreux et. al. 2008). This means that during these two stages of cell division, a 
chromosome pair fails to separate properly, leading to an anomaly in the usual genetic 
material of the cell. 
 
Basic trisomy 21 
 
In approximately 95 % of the individuals with Down syndrome, the anomaly results of a 
full extra copy of chromosome 21, as shown on Figure 5. This means that a patient has an 
abnormal karyotype of 47 chromosomes and the extra duplicated chromosome provides 
the cell with additional genetic information and causes the typical Down syndrome 
phenotype. This most common type is referred to as basic trisomy 21 (Dreux et. al. 2008). 
 
 
 
Some researches show that 97% of basic trisomy 21 occurs during meiosis and in only 
3% of the cases the nondisjunction of chromosome 21 occurs during mitosis. As 
mentioned earlier, incidence of Down syndrome highly depends on the age of the mother. 
Figure 5 –A female with basic Trisomy 21 has an 
abnormal karyotype of 47 chromosomes (Chen H, 
2006) 
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The role of parental influence on the condition will be discussed later in the paper. In the 
97% of basic trisomy 21 occurring in meiosis, 93% of the cases of nondisjunction comes 
from the mother and 4% from the father (Sherman et.al. 2007). 
 
 
Robertsonian translocation 
 
In 3-4% of Down syndrome cases a Robertsonian translocation can be observed (Dreux 
et. al. 2008). In order to have a full understanding of this type of Down syndrome, we 
need to get familiar with some terms.  
A normal human cell has 23 sets of chromosomes. In five of those sets (13, 14, 15, 21 
and 22) the centromere is situated near the end of the chromosome, causing one long and 
one short arm. These five chromosome sets are also referred to as acrocentric 
chromosomes.  
In Robertsonian translocation 21 a fusion between chromosome 21 and another 
acrocentric chromosome takes place. As shown on Figure 6, the long arm of chromosome 
21 attaches to another chromosome, usually chromosome 14 (Hatakeyama et.al. 2006). A 
person with this traslocation has a normal phenotype, however, there is a significantly 
higher risk of having a child with basic trisomy 21. Robertsonian translocation 21 as a 
subtype of Down syndrome is also referred to as “structural rearrangement of 
chromosome 21” (Dreux et. al. 2008). 
 
 
 
 
 
 
Figure 6 –Female with Robertsonian translocation 21. Part of 
chromosome 21 is attached to chromosome 14  (Chen H, 2006) 
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Trisomy 21 mosaicism 
 
In 2 % of Down syndrome cases a trisomy 21 mosaicism is observed. This means that the 
anomaly is present in only some of the cells or tissues in the body, causing them to have 
an abnormal karyotype of 47 chromosomes. Other cells or tissues have the normal 
chromosome set (Dreux et. al. 2008). A person with this type of the condition exhibits a 
broad spectrum of manifestation of the anomaly - some can show traits typical for basic 
trisomy 21 while others can have a normal phenotype. This difference happens because 
of the varying amount of trisomic cells for different individuals. This means that an 
individual with the condition will express more traits if more trisomic cells are present in 
his body (Papavassiliou et. al. 2009). 
 
 
Basic trisomy 21 – parental influences 
 
A thorough explanation of parental effects is presented in the research review paper done 
by Sherman, SL et.al. of NDSP (National Down Syndrome Project) in 2007.This paper 
reviews the study of NDSP of a total of 1884 infants - 907 with Down syndrome and a 
control group of 977 without the condition. As shown in Table 2, according to this 
research 93.2% of the nondisjunction errors occur in the maternal gametocyte, or in other 
words the oocyte. The majority of nondisjunctions are during the first stage of meiosis 
(Meiosis I). 
 
Table 2 - Origin of maternal nondisjunction in basic trisomy 21(Sherman et al. 2007) 
 
The most significant maternal factor is advanced maternal age. Nowadays more and more 
women tend to delay childbirth. Biologically, reasons for the high risk of nondisjunction 
in the oocyte can be all consequences of female aging- less number of maturing follicles, 
different hormonal changes in the ovaries and the body (Sherman et.al. 2007) and also 
insufficient amounts of important cell division proteins (Ghosh et. al. 2009). Figure 7 
shows how meiotic processes occur with errors. As seen in this research, the mother’s age 
is a risk factor for both meiotic processes – meiosis I and meiosis II. The only other risk 
factor for maternal nondisjunction is altered recombination. In these cases a 
nondisjunction occurs without the age factor (Sherman et. al. 2007). 
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Figure 7 - (a) Normal meiotic process (I, II). (b,c) Errors in meiotic processes (I, II) 
(Girirajan 2009)  
 
 
According to the same research, paternal influence is only 4.1% and the nondisjunctions 
of mitotic origin are only 2.7% (Sherman et. al. 2007). Logically the paternal 
nondisjunction of chromosome 21 occurs in spermatogenesis. According to studies the 
majority of errors coming from the father occur during meiosis II and only a small part in 
meiosis I. But the existence of a paternal age effect is controversial. Some researches 
suggest that there is no paternal age effect on the incidence of Down syndrome (Oliver et. 
al. 2009). Others state that there is one only when the mother’s age is over 35 years. And 
when the mother is young and has no significant risk of having a Down syndrome child, 
there is no paternal age influence (Fisch et. al. 2003). 
 
 
Prenatal screening 
 
In 1890 Ernest Starling discovered chemical messengers and named them hormones. In 
the beginning of 1903 Ludwig Fraenkel found that something is stimulating women’s 
body (today the well known pregnancy hormone hCG). In 1927, Selmar Aschheim and 
Bernhard Zondek described a test which identifies the present hCG in urine (today known 
as A-Z test). After the 1950's, research in different areas started and ultrasound screening, 
amniocentesis, fetoscopy and chorionic villus sampling were developed. All of those 
discoveries belong to one big group named prenatal screening techniques. They make it 
possible to determine the health and physical condition of an unborn fetus (National 
Institutes of Health, 2003; Woo 2002). 
 
All techniques can show the physical conditions of a fetus. Many different conditions can 
be detected, like heart problems, physical and genetic anomalies. In the case of a positive 
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result parents are faced with a difficult decision. As mentioned earlier, an advanced 
maternal age leads to a higher risk of developing genetic anomalies. Therefore a higher 
percentage of diagnostics are done for parents over the age of 35. Figure 8 illustrates 
more clearly the maternal age effect on the condition (Kids Health, 2009; March of 
Dimes, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 - Maternal age as effect on Trisomy 21 (Urquhart, D. 2009) 
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During different periods of the pregnancy, different diagnostic tests can be used. Most 
generally they can be divided into non- invasive prenatal screening techniques and 
invasive prenatal screening techniques. 
 
 
Non – invasive prenatal diagnostics for trisomy 21 
• Ultrasonography – external fetal monitoring and heartbeat 
 
- Nuchal Translucency 
 
• Triple levels test - maternal serums beta-HCG, AFP and estriol  
 
 
 Invasive prenatal diagnostics for trisomy 21 
 
• Amniocentesis  (AC) 
• Chorionic villlus sampling ( biopsy ) (CVS) 
• Quantitative fluorescent polymerase chain reaction (QF-PCR) 
 
(Klatt 2009; Leshin 2007) 
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Problem formulation 
 
Which prenatal screening techniques have the lowest risk and highest efficiency in 
detecting Down syndrome? 
 
Problem analysis 
 
“Risk of prenatal diagnosis” - In the wide range of prenatal screening techniques the 
word risk is associated with possible complications during a pregnancy that can affect the 
health of either the mother or the fetus, or even miscarriage.  
 
“Effectiveness of prenatal diagnosis” – A diagnostic test has a certain effectiveness 
combining different factors into account like percentage of correct detection of Down 
syndrome and percentage of miscarriages. 
 
Method 
 
The project is theory based, using scientific journals combined with relevant figures and 
tables. The results of the different papers was used to make an assessment so that we are 
able to answer the question of which prenatal screening techniques we think have the 
lowest risk and highest efficiency in the detection of Down syndrome. 
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Non-invasive Techniques Results 
 
 
FETAL NUCHAL TRANSLUCENCY 
 
Nuchal translucency (NT), as shown in Figure 9, is the appearance of subcutaneous fluid 
behind the neck of the fetus. (Kypros et.al., 2002). 
 
 
               
 
Chromosomal abnormalities can cause fluid accumulation. The chromosome number 21 
contains the gene that encodes collagen. In trisomy 21 this gene of collagen can be over 
expressed, this is the reason that leads to venous or lymphatic engorgement and the 
following detection of increased nuchal translucency. (Hyett et.al.,1999). 
 
Nuchal translucency thickness increases with crown-rump length (CRL), the normal NT 
measure for a CRL of 38 mm is 2.2 mm and 2.8 mm for a CRL of 84 mm (measured 
between the 11th and the 13th week of pregnancy). 
 
 
The measurement of the fetal NT thickness at the 11-13 weeks scan has been combined 
with the age of the mother to provide a very useful method of trisomy 21 scanning. We 
can detect up to 75% of pregnancies affected by trisomy 21. If we combine this technique 
with the triple test then we can detect Down syndrome in 90% of cases. (Kypros et.al., 
2002). 
 
 
The NT measuring scan provides other very valuable information such as chromosomal 
disorders, defects of the heart and arteries and skeletal dysplastias. (Skeletal Dysplastias 
Figure 9 - The fetus on the left has a normal nuchal translucency 
measurement (green line).The fetus on the right has an increased 
nuchal translucency measurement (green line) (DeVore GR (1999)) 
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are malformations on the bones and the joints). The most common dysplastia is “Spina 
Bifida” and it consists in the incomplete development of the spinal cord, shown below in 
Figure 10. 
 
 
 
 
While measuring fetal NT it is very important that all the professionals use the same 
criteria in order to achieve equal results: 
 
1. All the professionals performing scans must be appropriately trained and show a 
good knowledge of the management and features of fetal scanning. 
2. NT scan can be measured by transabdominal examination in up to 95% of the 
cases. For the remaining 5%; it will be measured via transvaginal sonography. 
3. The minimum fetal crown rump length (CRL) is 45 mm and the maximum is 84 
mm. The best time for measuring NT is in the 11th to 13th week. (CRL is the 
measurement of the fetus from the head to the end of the buttock, see Figure 11). 
 
 
Figure 10 - Spina Bifida development (Mayo 
Clinic, 2009) 
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4. Fetal NT increases with CRL, so it is very important to take into account the 
gestation period. 
5. NT should be measured when the fetus is in a neutral position. When the neck is 
extended the measurement can be increased up to 0.6 mm and when the neck is 
flexed it can be decreased up to 0.4 mm. 
6. It is extremely important to distinguish between fetal skin and amnion, since at 
this period of pregnancy both are shown as a thin membrane. This problem is 
easily solved by forcing the fetus to move from the amnion by making the mother 
cough or tapping the abdomen. 
7. In 5 to 10% of the cases the umbilical cord can be around the neck of the fetus, 
which can add 0.8% to the NT measurement. 
 
In fetuses with increased NT there is an increased level of atrial and brain peptide mRNA 
in fetal hearts, which suggests a presence of heart strain. 
The measurement of NT provides the most effective tool for detecting major 
abnormalities of the heart and great arteries. About half of these abnormalities are lethal 
or require urgent surgery. Specialists can identify most of these cardiac defects at the 20th 
week of pregnancy. (Kypros, et.al., 2002). 
 
The extracellular Matrix is the substance in which animal cells are embedded .The main 
component is glycoproteins, which are encoded on the chromosomes 21, 18 or 13. 
Increased levels of fetal NT also suggest an altered composition of the extracellular 
matrix causing a range of genetic syndromes associated with alteration of collagen 
metabolism, for example achondroplasia, a form of dwarfism that affects to one of every 
25.000 people, or Zellweger syndrome, a congenital disorder that consists in the absence 
or very low level of peroxisomes in the liver cells. It is important to mention the essential 
function of these organelles; they are in charge of getting the cell rid of all toxins 
(Campbell et.al. 2008). 
Figure 11 - Rump Length Measurement (DeVore 
GR, 1999) 
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Langdon Down reported in 1866 that the skin of individual affected with trisomy 21 
seemed “too big” for their bodies. In the 1990´s it was possible to detect by 
ultrasonography scan that an excess of skin is related to an increased measurement of NT. 
Every woman has a certain risk of developing a fetus with Down syndrome. In order to 
calculate this risk, fetal NT is combined with the maternal age and some background 
factors, like previous history of chromosomal defects, to provide a very effective method 
in detection of trisomy 21. (Kypros, et.al., 2002) 
 
 
 
TRIPLE TEST MARKERS (MATERNAL SERUM BIOCHEMISTRY) 
 
 
The most common methodology of screening is the one that follows:  
 
Women who choose to do a screening program are requested to take blood samples for 
serum biochemical screening (triple test) at the same time, they are asked some 
background questions related with Down syndrome history in the family, age, insulin 
dependent (in case of diabetes), etc. 
The ultrasound process is very simple and in the majority of the cases is fully completed 
in 20 minutes. If the fetus has a gestation prior to 11 weeks in the moment of the 
ultrasound (45 mm crown–rump length) the test is postponed until the correct period of 
gestation. If, on the other hand, the gestation is beyond 13 weeks (84 mm by crown–rump 
length), the AFT is measured. When the results are available they are introduced into the 
fetal database and a risk report is generated and it is available for the midwife to explain 
to the mother. Women with a high risk of trisomy 21 in the fetus or any of the fetuses (in 
the case of twin pregnancies) are redirected for chorionic villus sampling or 
amniocentesis and fetal karyotyping. (Spencer et.al. 2003) 
 
During the second trimester of pregnancy the following maternal serum tests are 
proposed: human chorionic gonadotrophin (HCG) or its variants (free β HCG, core 
HCG), α-fetoprotein (AFP) and uncojugated estriol. These three markers form the “triple 
test”. 
 
 
Triple Markers in detail:  
 
AFP (alpha-feto protein) is produced in the fetal liver and it is detectable in maternal 
blood and also in the amniotic fluid at 10-12 weeks of gestation. 
The most common cause for false elevated AFP levels is inaccurate date of pregnancy. 
AFP levels should be measured between the 15-20 weeks of gestation and we should 
notice that the concentration rises rapidly at this time (usually 20-75 ng/ml, typically 
35ng/ml). 
 The causes that lead to a low AFP value include inaccurate dating of pregnancy, as 
mentioned above, but most importantly; Downs’s syndrome affected fetus.(MedLabs 
Technical Bulletins, 2001) 
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HCG (human chorionic gonatropin) is a hormone produced by the placenta. 
When measured between the16-18 weeks the typical levels are between 20000-40000 
IU/L. The results are expressed in IU/L and as “multiples of the median” (MoM). It is 
calculated as HCG in IU/L divided by the median value adjusted for period of gestation, 
maternal age, weight and number of fetuses.  
High levels of HCG can help to predict the risk for a fetus to have Down’s syndrome. 
(MedLabs Technical Bulletins, 2001) 
 
 
uE3 (unconjugated estriol), is the most important marker during pregnancy. Estriol 
precursors are developed in the fetal liver and uE3 is synthesized in the placenta. 
Estriol levels increase during pregnancy. Low estriol levels are found in fetuses affected 
by Down’s syndrome. 
The results of measuring uE3 are expressed in ng/ml and as MoM, calculated as uE3 in 
ng/ml divided by the median value adjusted for gestation, maternal weight and number of 
fetuses.  (MedLabs Technical Bulletins, 2001) 
 
 
UE3 rise in concentration pararell to the growth of fetus and placenta. For that reason, it 
is a more sensitive indicator of altered fetal metabolism than any other marker. (Kim et. 
Al., 2000) 
 
 
As we can observe in Table 3, 107 women (participants on S. Kim et. Al., 2000 study) 
were below 0.75 MoM in the low uE3 group and 989 were above 0.75 MoM in the 
normal uE3 group. (Maternal age, week of pregnancy and maternal weight is practically 
equal in both groups). 
We can also observe that AFP levels are lower in the low uE3 group than in the normal 
one, while HCG levels are higher in the low uE3 group than in the normal one. 
 
 
 
 
 
 
Table 3 - Demographic variables between low and normal uE3 groups (Kim et.al. 2000) 
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During the first trimester, free β HCG is suggested. The triple test gives and evaluation of 
the risk. If this risk is higher than a predetermined level, an invasive technique will be 
suggested, usually amniocentesis. In the south of Belgium about 13000 tests are 
performed per year, and about 13% of the tests are performed during the first trimester. 
(Spencer et.al. 2003) 
 
The goal of the study from Verloes .et.al., from 2001, was to determine if the use of the 
triple test had a measurable impact on the epidemiology of trisomy 21.  
 
Data on trisomy 21 has been split into two groups: ‘Pre-triple test era’ (period from 1984 
to 1989) when most amniocenteses were undertaken for maternal age or ultrasound 
anomalies. The triple test was established in Belgium in 1990. The period 1990–1992 is 
considered as the ‘transition era’. The period from 1993 to1998 is the post ‘triple test era’ 
during that time the triple test has been offered in South Belgium. See Table 4 for 
detailed data (Verloes et.al. 2001) 
 
 
 
Table 4- Comparison of the detection rate of T21 in the periods 1984-1989 and 1993-1998. 
(Verloes, A. et.al. 2001) 
One important point is the huge variation in the number of trisomies per year, from 39126 
births in 1987 to 41108 births in 1992. It is also significant the increase of births in the 
older age group in such a short period of time (Table 5). 
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Table 5 – Anticipated trisomy (T21) births in South Belgium, based on demographic data from 
1987 and 1992 (Verloes, A. et.al. 2001) 
It is expected that the use of the triple test combined with the measurement of nuchal 
translucency in the first trimester of pregnancy will increase the detection rate of trisomy 
21 in the future. (Verloes et.al. 2001) 
 
 
Triple marker test and racial differences. 
 
 
Pregnant woman who have a fetus affected by trisomy 21 present low concentrations of 
AFP, increased human chorionic gonadotropin (hCG) and low concentrations of 
unconjugated estriol (uE3). (Benn et.al., 1997) 
As we can see in Figure 12 and Table 6 there are several racial differences when 
observing triple markers: 
AFP concentrations are higher in black patients than in white patients. It is also noticed 
that hCG concentrations are higher in black patients. UE3 values don’t show such a big 
difference between black and white patients. 
The following data correspond to a study realized to 21480 singletons at 15 to 23 weeks 
of gestation. Four races were used: white, black, Hispanic, and other (mainly Oriental and 
Indian) 
For each race group the patients were sorted into weight intervals of 15 pounds, and the 
median MoM values were calculated for each interval. (Benn et.al., 1997) 
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Fig.ure 12 - AFP median values at 15-23 weeks of gestation (A). hCG median values at 15-21 
weeks of gestation (B), and uE3 values at 15-21 weeks of gestation (C) for white, black Hispanic, 
and other patients (espressed relative to the value for white patients) 
 
The results of this study show that median values for second-trimester maternal serum 
AFP, hCG, and uE3 are different taking in consideration gestational period and races or 
ethnic groups. (Benn et.al., 1997). 
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Table 6 - Median AFP, hCG and uE3 concentrations as function of gestational age and 
race/ethnicity of the patient (Benn et.al. 1997) 
 
 
 
 
 
 
Several studies have also reported differences in the results of prenatal screening between 
Caucasian and Asian populations. Second-trimester serum samples were collected from 
Japanese pregnant women between May 1993 and March 1994. The blood was separated 
and the serum was sent to the laboratory in Santa Fe, New Mexico. The samples were 
tested for alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and 
unconjugated estriol The results were combined with background information such as 
date of birth, maternal age at pregnancy, gestational period, weight, number of fetuses, 
insulin dependency (in case of diabetes), and family history of Down syndrome. 
The rate of pregnancies affected by Down syndrome in Japan is around 1 per 1000 births, 
and the maternal age risk in developing a fetus with trisomy 21 is the same as the one in 
western countries. 
 
In a preliminary study from Onda.et.al. from1996, a total of 503 samples were obtained 
from the 17th week of native Japanese pregnancies. The median maternal age was 30.2 
years. The median levels of AFP, hCG, and estriol (uE3) for each week of pregnancy, 
were all higher than the corresponding levels in western country's pregnancies (Table 7). 
The median weight of the Japanese women is 53.1 kg and 63.5 kg for Caucasian women. 
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This information frames the relation between the weight of woman and the level of AFP, 
hCG and estriol. 
 
These results have lead to modifications to adjust weight equations (the concentration per 
change in weight is the same, only averages change). (Onda.et.al.,1996). 
 
 
Table 7 - Effect of maternal weight on AFP, hCG and uE3. Measurements in 503 native Japanese 
pregnancies. (Onda, T. et.al, 1996) 
 
 
The results of the preliminary study indicate that second-trimester values of maternal 
serum AFP, HCG, and uE3 in a population of native Japanese women are significantly 
higher on average than those established for a U.S. Caucasian population. Serum samples 
from native north-American and native Japanese populations were analyzed in the same 
laboratory, the different values cannot be related to different techniques or 
methodologies. 
 
 
Twins versus single pregnancies 
 
 
During the last two decades the increased maternal age and the use of assisted 
reproduction technology have raised dramatically .This has led to a high amount of cases 
of twin pregnancies with risk of having any kind of chromosomal defects. (Maymon et.al 
1999). 
Triple test in twin pregnancies poses difficulties due to imprecise information for each of 
the twins as individual. For this reason, the preferable screening method for DS is NT 
measurement; it has been observed that NT in fetuses with DS is similar to that found in 
affected singletons. 
NT results, including the number of fetuses and CRL, are introduced into the fetal 
database. The calculated risk of having a DS fetus is calculated on basis of the maternal 
age and the gestational age, multiplied by the ratio upon the deviation from the normal 
NT thickness for CRL. 
A pregnancy is considered as ‘screen positive’ if the risk of having a DS baby is equal or 
higher than 1:380. 
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The study group includes 60 pregnant women with twins. Each co-twin is matched with a 
singleton having a similar CRL and maternal age, thus there were 120 fetuses in the 
control group. (Maymon et.al., 1999). 
 
As shown in Table 8 biochemical screening demonstrated a significant difference 
between the two groups. 9 of the 60 pregnancies (15 %) were found to be screen positive 
compared with 7 of the 120 control cases (6%).  
 
 
 
 
 
Table 8 -  NT and triple test results in the study and control groups. Rate ª  per 60 pregnancies in 
the study group  and per 120 pregnancies in the control group.(Maymon et. al. 1989) 
 
 
 
 
 
Invasive techniques 
 
Amniocentesis 
 
The procedure of amniocentesis provides detection of genetic disorders, through a sample 
of amniotic fluid. After the procedure, the sample is then cultivated and analyzed through 
a series of cytogenetic tests that are done to determine any genetic abnormalities there 
may be. The procedure takes between 3 and 4 weeks for results (Podobnik et.al, 1997). 
Amniocentesis is usually not performed unless the parent is in at high-risk of having a 
child with a genetic defect. Maternal serum screening, as well as age play a factor in the 
risk assessment but an ultrasound can also show if a fetus is likely to have any 
malformations. Any parent with a genetic disorder risk higher than 1/250 is usually given 
the option of having amniocentesis since this is probability generally constitutes a high 
risk of genetic abnormality. The parent, although, has a right to refuse or request one 
(Muller et.al, 2002). The risk of losing the child is 0.86% higher according to Muller 
et.al, 2002. 
 
QF-PCR 
Quantitative fluorescent polymerase chain reaction (QF-PCR) is another method used for 
detecting any possible chromosome abnormalities in a fetus. The test gives results within 
24 to 48 hours (Cirigliano et.al, 2009). It is a relatively new procedure, developed within 
the last 15 years. 
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The test is 95% effective in detecting abnormalities (Cirigliano et.al, 2009). Most of the 
failed tests were due to contamination of samples with maternal cells, or the samples 
were not fresh, having been in the culture for too long. For detecting Down syndrome, the 
QF-PCR test was just as effective as amniocentesis and other cytogenetic tests such as 
CVS.  
 
It should be noted that none of the studies had any false positives or negatives although it 
was the same case for the cytogenetic tests (Cirigliano et.al, 2009). 
 
Table 9 - Results of 43,000 consecutive clinical samples tested with QF-PCR and 
cytogenetics (Cirigliano et.al, 2009) 
 
Karyotype QF-PCR Cytogenetics 
46 XX; 46 XY 41 019 41 178 
47 XX+21; 47 XY+21 751 753 
47 XX+18; 47 XY+18 298 299 
47 XX+13; 47 XY+13 127 127 
Failed tests 21 52 
Total abnormalities 1608 1741 
 
 
Table 9 shows the results of 43,000 consecutive clinical samples tested with QF-PCR and 
cytogenetics. This table demonstrates how accurate the QF-PCR test is compared to the 
cytogenetics. For the trisomy 21 karyotype, the QF-PCR test detected all but two samples 
as shown in line 2 of the table. In the study done, these two tests failed due to maternal 
cell contamination. All in all, the QF-PCR was able to get results from tests that normal 
cytogenetics were not, although the cytogenetics found more total abnormalities. 
 
 
CVS 
 
Chorionic villus sampling (CVS) is a screening method which uses a sample from the 
placenta of an unborn child. The scan is done with the guidance of ultrasound. It is 
performed in the second or third trimester, most commonly in cases where noninvasive 
techniques have determined a higher risk of abnormalities. The results are available in 
approximately one week (Podobnik et.al, 1997). 
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Table 10 shows the variety of procedure in different European countries as well as their 
abortion laws (a statistical data from „ Special report: prenatal screening policies in 
Europe” (Boyd et.al. 2005)).  
 
Table 10 – Statistical data for prenatal screening techniques in European countries and their 
abortion laws. (Boyd et. Al. 2005) 
Country Prenatal Techniques 
 
Abortion Law Procedure 
 
 
 
Croatia 
 
 
- Double test plasma protein A  
and free beta hCG 
- Triple test (hCG, AFP, uE3 (estriol)) 
- Amniocentesis (AC) 
- Choronic villus sampling (CVS) 
 
From 1978 abortion is 
allowed after 10 weeks of 
pregnancy. 
 
Denmark 
 
 
From 1994 till 2004, CVS and AC were 
tests only for women older than 35 
years. Younger women could have those 
tests if they were in a high risk group of 
having a child with Downs Syndrome. 
 
- Amniocentesis (AC) 
- Choronic villus sampling (CVS) 
- Triple test ( hCG, AFP, uE3 (estriol) 
- Ultrasonography 
- First trimester serum screening 
 
 
 
After 2004 prenatal 
screenings policy law was 
changed and all women 
were allowed to have 
those tests. According to 
Danish laws after 12 
weeks of pregnancy, if a 
commission decides that 
the fetus has a significant 
anomaly, the mother can 
have an abortion until the 
24th week of the 
pregnancy. 
 
 
France 
 
 
- Nuchal Translucency - Ultrasound 
- Maternal serum screening 
- Amniocentesis 
- Chorionic villus sampling 
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Germany 
 
 
 
- Amniocentesis 
- Maternal serum screening 
- Triple test (hCG, AFP, uE3 (estriol) 
- Beta-hCG test 
- Ultrasonography 
 
According to German laws 
an abortion can be made 
only until the12th week of 
pregnancy. 
 
 
 
Ireland 
 
 
 
- Amniocentesis 
- Choronic villus sampling (CVS) 
- Ultrasonography 
 
In Ireland abortion is 
illegal, except in cases 
when the mother’s life is 
endangered. 
 
 
 
The 
Netherlands 
 
 
- Nuchal Translucency - Ultrasound 
- Triple test (hCG, AFP, uE3 (estriol) 
- Amniocentesis 
- Choronic villus sampling (CVS) 
 
An abortion is allowed 
until the 24th week of 
pregnancy. 
 
 
Sweden 
 
 
 
- Ultrasonography 
- Choronic villus sampling (CVS) 
 
 
Abortion is allowed from 
18th – 22nd week of 
pregnancy. 
 
 
Each country has its own laws and system for detecting Down’s syndrome. But prenatal 
screening is not the only method for discovering the genetic disease. There are a few 
mathematical methods where using computer calculations, it is possible to calculate the 
probability of having a child with Down syndrome. These techniques, however, will not 
be explained in this project. 
 
Ethics 
 
Living with Down syndrome is not easy and neither is raising a child with the disease. 
There are some organizations that can help parents with techniques that will help them in 
raising their child. Furthermore, the organizations can help with finding suitable schools 
and thus establishing a better social environment for the child. 
 
There are also moral dilemmas associated with a positive result. Aborting a pregnancy is 
a decision that can bring religious and personal conflicts. Caring for a child with Down 
syndrome also brings financial implications and the waiting parents must also be 
psychologically and mentally ready to take care of a child with a genetic disorder. 
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Discussion 
 
 
When using amniocentesis and running cytogenetic test on the samples, it gives a very 
accurate result, and is a good method for detecting multiple genetic diseases, including 
Down syndrome. It does, however, have an increased risk of fetal loss compared to 
mothers than have not had the procedure. The time it takes for results is also very long. 
This can cause increased stress and worry in mothers during the waiting period. CVS is 
also an effective tool in detecting Down syndrome, but it is carried out too late in the 
pregnancy. This results in the mother not having the option of aborting the pregnancy, if a 
positive result is obtained. 
 
The best invasive technique, in our opinion, is the quantitative fluorescent polymerase 
chain reaction (QF-PCR). This test cuts down on the waiting period for results, 
preventing unnecessary stress and anxiety to the waiting mother. When obtaining samples 
to test, QF-PCR uses the same method as amniocentesis, so an increased risk of fetal loss 
is still to be expected. 
 
All invasive techniques provide an accurate result in detecting Down syndrome. We feel 
that it is not just the accuracy of the result that is relevant however. The waiting for test 
results can be a worrying time for a waiting mother. The invasive techniques are usually 
only used if a high-risk of genetic abnormality is determined. The parent will already be 
under stress from this news, so it is important to cut the waiting time on results down to 
as little as possible. The QF-PCR test combines a high level of efficiency, with a low 
waiting period. It is also cheaper, so it will be a useful tool in poorer countries. 
 
 
Conclusion 
 
The combination of Nuchal Translucency with background information of the mother, 
age and history of trisomy 21 in the family, can detect 75% of the cases of trisomy 21. If 
the triple test result is also taken into consideration, this percentage can increase detection 
up to 90%. As for using invasive techniques, we get a very high level of accuracy, using 
both amniocentesis and the QF-PCR. The CVS scan also gives good results, but we 
disregard it in our case, since the scanning for Down syndrome is performed too late for 
an eventual abortion to be relevant. In our opinion, the results of the different scientific 
papers support the previous conclusion that the level of accuracy of QF-PCR is very high, 
compared to the little time it takes for the results to be obtained, and should be considered 
a viable alternative to the traditional cytogenetics.  
 
In conclusion, a combination of Nuchal Translucency and Triple test will provide high 
detection efficiency of Trisomy 21. In a case of a positive result, the invasive technique 
QF-PCR can be used, in order to obtain an exact result. The results from this combination 
of tests can prevent an abortion that should not have taken place. 
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